Viridian Therapeutics, Inc. (VRDN)
NASDAQ · Manufacturing · Pharmaceutical preparations
VRDN price, last 12 months
Key stats
- Previous close
- $30.12
- Open
- $30.33
- Day range
- $29.92 – $31.51
- 52-week range
- $13.18 – $34.29
- Volume
- 4M
- Avg volume (20 days)
- 3M
- Market cap
- $3.5B
Performance
Technicals and fundamentals
About Viridian Therapeutics, Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $3.5B